Neuro3 Therapeutics (Neuro3), a biotechnology company specializing in central nervous system (CNS) diseases with operations in Suzhou, China, and the US, has announced the signing of an exclusive license and option agreement with Denmark-based Lundbeck (OTCMKTS: HLUBF). This deal grants Neuro3 a global license to the intellectual property encompassing two clinical stage and one pre-clinical KCNQ2 activator programs, marking a significant step in the advancement of epilepsy treatments.
Development and Commercialization Plan for KCNQ2 Activator Programs
Under the terms of the agreement, Neuro3 will be responsible for the development of the KCNQ2 activator programs up to the proof of concept stages. Upon reaching this milestone, Lundbeck will have the option to co-develop and co-commercialize the programs with Neuro3. Additionally, Lundbeck retains the right to exclusively license back the rights in certain territories, should they choose to do so.
KCNQ2 Activator: A Promising Target for Epilepsy Treatment
KCNQ2 is an ion channel that has been identified as a valid target for the treatment of epilepsy, including rare forms of the disease. The potential of KCNQ2 activators in managing epilepsy offers hope for patients and underscores the importance of this collaboration between Neuro3 and Lundbeck.-Fineline Info & Tech
